SEP 18·SEC EDGARLow
Doogan Declan purchased $102K of TENX
Doogan Declan purchased 53,000 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.92 ($0.10M total) on 2026-09-16.
StockNASDAQ · US · USDHealthcare · Biotechnology
$TENX
TENAX THERAPEUTICS, INC.
AlphAI earnings readsecond quarter of 2026 · JUL 31Tenax Therapeutics reported a second-quarter net loss of $17.8 million as Phase 3 development spending increased, while cash and cash equivalents were $118.0 million and the Company expects to fund operations through the second quarter of 2028.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $TENXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $TENX in the last 7 days.
Insider · 30dAll trades →
- Buys
- $3.3M 9 txs
- Sells
- — 0 txs
ADAR1 Capital Management, LLC5× · $3.2M
10b5-1 share of filings0%
Top stories · $TENXMore →
SEP 16·SEC EDGAR
Giordano Christopher Thomas purchased $20K of TENX
Giordano Christopher Thomas (CEO) purchased 10,850 shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.85 ($1.82–$1.88) across 2 trades over 2026-09-11 to 2026-09-15.
SEP 16·SEC EDGAR
STAAB THOMAS R II purchased $11K of TENX
STAAB THOMAS R II (Chief Financial Officer) purchased 5,675 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.94 on 2026-09-11.
TENX sentiment & insider activity
Recent TENX coverage spans insider activity, financial news and technology.
In the last 30 days, TENX insiders filed 9 SEC Form 4 transactions — 9 purchases ($3.3M) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 5 filings.
What's driving TENX
Insider purchase may signal confidence, modest upside potential.
Small insider purchase signals confidence but limited market impact due to modest size.
Small insider purchase may signal confidence but limited market impact due to modest size.
The loss of a large institutional holder may pressure TENX price modestly.
Insider purchase suggests confidence but size is modest relative to market cap.
AlphAI scores every news story that mentions TENX with an AI model for sentiment and relevance, and aggregates insider trades from TENAX THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TENX
Score
Doogan Declan purchased $102K of TENX
Doogan Declan purchased 53,000 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.92 ($0.10M total) on 2026-09-16.
1 min readGiordano Christopher Thomas purchased $20K of TENX
Giordano Christopher Thomas (CEO) purchased 10,850 shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.85 ($1.82–$1.88) across 2 trades over 2026-09-11 to 2026-09-15.
1 min readSTAAB THOMAS R II purchased $11K of TENX
STAAB THOMAS R II (Chief Financial Officer) purchased 5,675 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.94 on 2026-09-11.
1 min readING Groep reports zero stake in Tenax Therapeutics (TENX)
ING Groep N.V. and ING Capital Markets LLC filed an amended Schedule 13G/A, disclosing zero ownership in Tenax Therapeutics (TENX) as of September 11, 2026. The filing indicates no voting or dispositive power over Tenax's common stock, with 37,423,917 shares outstanding as of July 28, 2026.
1 min readADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.6M of TENX (indirect holdings)
ADAR1 Capital Management, LLC purchased 900,000 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at $1.78 ($1.60M total) on 2026-09-03. Filed jointly with Schneeberger Daniel (10% owner).
1 min readOne manager just reported a 14% holding in Tenax Therapeutics (TENX)
ADAR1 Capital Management and its manager, Daniel Schneeberger, reported a 14% stake in Tenax Therapeutics (TENX), owning 5,257,389 shares as of July 28, 2026. They also hold warrants for additional shares, excluded due to a 4.99% ownership cap.
2 min read
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.
2 min readInvestment funds tied to Tenax (TENX) 10% owner just bought more stock
ADAR1 Capital Management, LLC, a 10% owner of Tenax Therapeutics (TENX), reported buying 770,333 shares of common stock from August 31 to September 2, 2026, at an average price of $1.79 per share, ranging from $1.77 to $1.80. The purchases were made indirectly through private investment funds managed by ADAR1.
1 min readADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.4M of TENX (indirect holdings)
ADAR1 Capital Management, LLC purchased 770,333 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.79 ($1.79–$1.80, $1.38M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Schneeberger Daniel (10% owner).
1 min read
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E
2 min read